pegrizeprument - Veloxis Pharmaceuticals
Alternative Names: Anti CD28 monoclonal antibody - OSE Therapeutics; FR-104; VEL-101Latest Information Update: 11 Jun 2024
At a glance
- Originator Effimune
- Developer Biomedical Primate Research Center; Janssen Biotech; Nantes University Hospital; OSE Immunotherapeutics; Veloxis Pharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action CD28 antigen inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Transplant rejection
- No development reported Encephalomyelitis; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Uveitis
Most Recent Events
- 05 Jun 2024 Adverse events and efficacy data from phase I/II trial in Transplant rejection (In adults, In the elderly) released by company (IV)
- 11 Dec 2023 Interim safety data from a phase I/II trial in Transplant rejection released by OSE Immunotherapeutics
- 24 Jul 2023 Veloxis Pharmaceuticals plans a phase II trial in Transplant rejection (SC)